Neumora Therapeutics is trading 8.64% up at $0.84, with no fresh company-specific catalyst identified for September 17, 2026; the move appears primarily tied to a broader global-market recovery.
- The latest investor-relations listing shows the most recent 2026 release was the August 14 second-quarter update, not a new overnight announcement.
- S&P 500, Nasdaq, and Dow futures were all up more than 0.5% after the prior session’s Federal Reserve-driven weakness.
- The stock remains sharply lower across the past week, suggesting a volatile rebound.